Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine

Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine Publisher

Farahmand B¹ ; Sadat Larijani M² ; Fotouhi F¹ ; Biglari A³ ; Sorouri R⁴ ; Bagheri Amiri F⁵ ; Eslamifar A² ; Jalali T⁶ ; Salehivaziri M⁶ ; Banifazl M⁷ ; Dahmardeh S⁸ ; Eshratkhah Mohammadnejad A¹ ; Bavand A² ; Tavakoli M⁶ Show All Authors

Farahmand B¹
Sadat Larijani M²
Fotouhi F¹
Biglari A³
Sorouri R⁴
Bagheri Amiri F⁵
Eslamifar A²
Jalali T⁶
Salehivaziri M⁶
Banifazl M⁷
Dahmardeh S⁸
Eshratkhah Mohammadnejad A¹
Bavand A²
Tavakoli M⁶
Verezbencomo V⁹
Mostafavi E⁵
Noori Daloii H¹⁰
Ashrafian F²
Saberpour M¹
Ramezani A²

Show Affiliations

1. Department of Influenza and Other Rrespiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
2. Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran
3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. IPI Directorate, Pasteur Institute of Iran, Tehran, Iran
5. Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
6. COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran
7. Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran
8. Vaccination Department, Pasteur Institute of Iran, Tehran, Iran
9. Finlay Vaccine Institute, Havana, Cuba
10. Health and Safety Department, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran

Source: Heliyon Published:2023

Abstract

COVID-19 pandemic has been managed through global vaccination programs. However, the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus as a protein subunit vaccine was investigated in immunized health care workers by COVAXIN (BBV152). The booster vaccine was recommended at least three months post the second dose of COVAXIN. Sera collection was done before and after each injection. SARS-CoV-2 PCR test was done monthly to detect any asymptomatic and symptomatic vaccine breakthrough. 47.9 and 24.3% of the participants were seronegative for anti-N and anti-S antibodies three months after the second dose of COVAXIN, respectively. On average, fold-rises of 70, 93, 8 and mean-rises of 23.32, 892.4, 5.59 were recorded regarding neutralizing antibody, quantitative and semi-quantitative anti-Spike antibody, respectively. Anti-Spike and neutralizing antibodies seroconversion was seen 59.3% and 45.7%, respectively. The vaccine breakthrough assessment showed that all the isolated samples belonged to SARS-CoV-2 Delta variant. PastoCovac Plus boosting is strongly recommended in combination with inactivated vaccine platforms against SARS-CoV-2. © 2023

Related Docs

View other Related Docs

1. Immunogenicity and Safety of Heterologous Boost Immunization With Pastocovac Plus Against Covid-19 in Chadox1-S or Bbibp-Corv Primed Individuals, PLoS Pathogens (2023)

2. Pastocovac and Pastocovac Plus As Protein Subunit Covid-19 Vaccines Led to Great Humoral Immune Responses in Bbip-Corv Immunized Individuals, Scientific Reports (2023)

3. The Impact of Abo Blood Types on Humoral Immunity Responses and Antibody Persistency After Different Covid-19 Vaccine Regimens, Journal of Medical Virology (2024)

4. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)

5. Safety and Immunogenicity of Corenapcin, a Sars-Cov-2 Mrna Vaccine, As a Fourth Heterologous Booster in Healthy Iranian Adults: A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Clinical Trial With a Six-Month Follow-Up, International Immunopharmacology (2024)

6. Comparative Assessment of a Covid-19 Vaccine After Technology Transfer to Iran From Critical Quality Attributes to Clinical and Immunogenicity Aspects, Scientific Reports (2024)

7. Efficacy of Mrna, Adenoviral Vector, and Perfusion Protein Covid-19 Vaccines, Biomedicine and Pharmacotherapy (2022)

8. Iran’S Research Prioritization: Are We Meeting the Goals? a Study Based on Clinical Trial Registry Data, PLoS ONE (2024)

Experts (# of related papers)

View all Related Experts

Alireza Biglari (3)

Nima Rezaei (2)

Style	Citing Format
MLA	Farahmand B, et al.. "Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine." Heliyon, vol. 9, no. 10, 2023, pp. -.
APA	Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, Eslamifar A, Jalali T, Salehivaziri M, Banifazl M, Dahmardeh S, Eshratkhah Mohammadnejad A, Bavand A, Tavakoli M, Verezbencomo V, Mostafavi E, Noori Daloii H, Ashrafian F, Saberpour M, Ramezani A (2023). Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine. Heliyon, 9(10), -.
Chicago	Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, Eslamifar A, et al.. "Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine." Heliyon 9, no. 10 (2023): -.
Harvard	Farahmand B et al. (2023) 'Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine', Heliyon, 9(10), pp. -.
Vancouver	Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, et al.. Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine. Heliyon. 2023;9(10):-.
BibTex	@article{ author = {Farahmand B and Sadat Larijani M and Fotouhi F and Biglari A and Sorouri R and Bagheri Amiri F and Eslamifar A and Jalali T and Salehivaziri M and Banifazl M and Dahmardeh S and Eshratkhah Mohammadnejad A and Bavand A and Tavakoli M and Verezbencomo V and Mostafavi E and Noori Daloii H and Ashrafian F and Saberpour M and Ramezani A}, title = {Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine}, journal = {Heliyon}, volume = {9}, number = {10}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Farahmand B AU - Sadat Larijani M AU - Fotouhi F AU - Biglari A AU - Sorouri R AU - Bagheri Amiri F AU - Eslamifar A AU - Jalali T AU - Salehivaziri M AU - Banifazl M AU - Dahmardeh S AU - Eshratkhah Mohammadnejad A AU - Bavand A AU - Tavakoli M AU - Verezbencomo V AU - Mostafavi E AU - Noori Daloii H AU - Ashrafian F AU - Saberpour M AU - Ramezani A TI - Evaluation of Pastocovac Plus Vaccine As a Booster Dose on Vaccinated Individuals With Inactivated Covid-19 Vaccine JO - Heliyon VL - 9 IS - 10 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract